Australian regulator TGA warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic
TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorderFollow our Australia news live blog for latest updatesGet our breaking news email, free app or daily news podcastAustralia’s medicines regulator has issued warnings…
By · July 24, 2026 · 1 min read
This article was originally published by
The Guardian World
and is republished here under license.
TGA says product information for some diabetes and weight loss drugs updated with warning of NAION disorder
Australia’s medicines regulator has issued warnings for several type 2 diabetes and obesity-related treatments – including Ozempic and Mounjaro – over the potential to cause a “rare but severe” eye disorder that could lead to blindness.
The Therapeutic Goods Administration’s (TGA) warning came after several GLP-1 RA medicines, marketed in Australia as Ozempic, Wegovy and Mounjaro among other products, have been linked to 36 cases of the condition.
Leave a Reply